Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOP-AF
jRCTs031220608Recruiting
- Sponsor
- Kowa Company, Ltd.
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of tofogliflozin in Atrial fibrillation (AFib) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Kowa Company, Ltd. Primary endpoint: AF free survival rate at 48 weeks after catheter ablation. Started May 2023; status: recruiting.
02
Drugs
tofogliflozin
03
Conditions
Atrial fibrillation (AFib)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs031220608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220608.